Cheon, Jae Hee; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul,
Paridaens, Kristine; Ferring International Center, St-Prex, Switzerland.
Awadhi, Sameer Al; Department of Gastroenterology, Rashid Hospital, Dubai Health Authority, Dubai,
Begun, Jakob; Department of Gastroenterology, Mater Hospital Brisbane, Brisbane, Australia.
Fullarton, John R; Violicom Medical Limited, Aldermaston, UK.
Louis, Edouard ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive ; Department of Hepato-Gastroenterology and Digestive Oncology, University and
Magro, Fernando; Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of ; Department of Gastroenterology, São João University Hospital Center, Porto,
Marquez, Juan Ricardo; Instituto de Coloproctologia ICO Clinica Las Americas, Medellin, Colombia.
Moschen, Alexander R; Department of Internal Medicine, Gastroenterology and Hepatology, Kepler
Narula, Neeraj; Division of Gastroenterology, Department of Medicine and Farncombe Family
Rydzewska, Grazyna; Clinical Department of Internal Medicine and Gastroenterology with Inflammatory ; Collegium Medicum, Jan Kochanowski University, Kielce, Poland.
Dignass, Axel U; Department of Medicine I, Agaplesion Markus Hospital, Goethe-University,
Travis, Simon Pl; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
1. Dignass AU, Paridaens K, Al Awadhi S, et al. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol 2022;57:424-431.
2. Gisbert JP, Gomollón F, Hinojosa J, López San Román A. Adherence of gastroenterologists to European Crohn’s and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. J Crohns Colitis 2010;4:567-574.
3. Pedersen N, Thielsen P, Martinsen L, et al. eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis 2014;20:2276-2285.
4. Moshkovska T, Stone MA, Smith RM, Bankart J, Baker R, Mayberry JF. Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. Inflamm Bowel Dis 2011;17:1874-1881.
5. Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of oral, topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and network meta-analysis. J Crohns Colitis 2021;15:1184-1196.
6. Sood A, Ahuja V, Midha V, et al. Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease. Intest Res 2020;18:355-378.
7. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570-1583.
